Effectiveness of group cognitive behavioral therapy with mindfulness in end-stage renal disease hemodialysis patients

Article information

Kidney Res Clin Pract. 2018;37(1):77-84
Publication date (electronic) : 2018 March 31
doi : https://doi.org/10.23876/j.krcp.2018.37.1.77
1Department of Psychiatry, Sanggye Paik Hospital, Seoul, Korea
2Department of Psychiatry, Inje University College of Medicine, Busan, Korea
3Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea
4Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
5Department of Psychiatry, SMG-SNU Boramae Medical Center, Seoul, Korea
6Department of Psychiatry and Behavioral Science, Seoul National University College of Medicine, Seoul, Korea
7Police Trauma Center, Seoul, Korea
8Department of Critical Care Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea
9Choi Hee-Jeong Internal Medicine Clinic, Seoul, Korea
10Department of Psychiatry, Kangdong Sacred Heart Hospital, Seoul, Korea
11Department of Psychiatry, Hallym University College of Medicine, Chuncheon, Korea
Correspondence: Chun Soo Lim, Department of Internal Medicine, SMG-SNU Boramae Medical Center, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Korea. E-mail: cslimjy@snu.ac.kr. ORCID: http://orcid.org/0000-0001-9123-6542
*Bo Kyung Sohn and Yun Kyu Oh contributed equally to this study as the co-first authors.
Received 2017 August 17; Revised 2018 February 09; Accepted 2018 February 20.

Abstract

Background

Many patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD) experience depression. Depression influences patient quality of life (QOL), dialysis compliance, and medical comorbidity. We developed and applied a group cognitive behavioral therapy (CBT) program including mindfulness meditation for ESRD patients undergoing HD, and measured changes in QOL, mood, anxiety, perceived stress, and biochemical markers.

Methods

We conducted group CBT over a 12-week period with seven ESRD patients undergoing HD and suffering from depression. QOL, mood, anxiety, and perceived stress were measured at baseline and at weeks 8 and 12 using the World Health Organization Quality of Life scale, abbreviated version (WHOQOL-BREF), the Beck Depression Inventory II (BDI-II), the Hamilton Rating Scale for Depression (HAM-D), the Beck Anxiety Inventory (BAI), and the Perceived Stress Scale (PSS). Biochemical markers were measured at baseline and after 12 weeks. The Temperament and Character Inventory was performed to assess patient characteristics before starting group CBT.

Results

The seven patients showed significant improvement in QOL, mood, anxiety, and perceived stress after 12 weeks of group CBT. WHOQOL-BREF and the self-rating scales, BDI-II and BAI, showed continuous improvement across the 12-week period. HAM-D scores showed significant improvement by week 8; PSS showed significant improvement after week 8. Serum creatinine levels also improved significantly following the 12 week period.

Conclusion

In this pilot study, a CBT program which included mindfulness meditation enhanced overall mental health and biochemical marker levels in ESRD patients undergoing HD.

Introduction

Many patients with end-stage renal disease (ESRD) are faced with lifestyle restrictions in diet, fluid intake, and medication. They must also adhere to hemodialysis (HD) or peritoneal dialysis schedules. Therefore, they often feel they have lost control of their lives and experience poor quality of life (QOL) [1,2]. These feelings induce non-adherence to medical guidelines, which may exacerbate medical problems [1].

The rate of non-adherence to diet, fluid intake, and medication regimens has been reported to range from 30% to 60% in ESRD patients receiving dialysis [1]. Depression is common in ESRD patients (20–30%) [3,4], and causes reduced QOL [5,6], poor adherence to dialysis treatment [7], and increased mortality [8] and suicidality [9].

Pharmacological intervention for depression is ineffective for many ESRD patients [10]; therefore, non-pharmacological interventions have been used to treat psychiatric problems including depression. Strategic self-presentation, kidney disease education, supportive psychotherapy, and group intervention have been shown to reduce depression and progression of renal disease [1115]. Individual cognitive behavioral therapy (CBT) has been shown to improve depressive mood and QOL [12]. Mindfulness-based cognitive therapy (MBCT) [16], which is related to mindfulness-based stress reduction (MBSR) [17], also shows efficacy in preventing relapse of depression. MBSR can enhance adaptation to distress from chronic illness, and has a strong potential for benefit for ESRD patients [17]. A previous study described telephone-adapted MBSR for patients awaiting kidney transplantation [18], but few studies have applied MBSR or MBCT to patients with ESRD.

Patients with ESRD need intervention focused on their psychological characteristics to reduce medical non-adherence. Individual CBT programs are difficult to apply in clinical settings due to lack of time and the limited number of experts available. Therefore, in this pilot study, we developed a 12-week group CBT program that included mindfulness meditation, anger management, and communication skills training based on conventional CBT [19]. We measured overall QOL, mood, anxiety, and distress in ESRD patients undergoing HD and suffering from depression, at baseline and after eight and 12 weeks of group CBT to evaluate its effectiveness and feasibility.

Methods

Participants

Seven participants (three women and four men) were enrolled in the study. Due to their HD schedules, we divided them into three groups of 2 to 3 participants each. Participants completed 12 one-hour sessions with the same psychologist once a week in the same room. All participants underwent HD for four hours, three times per week. Participants were patients at the SMG-SNU Boramae Medical Center and at one local clinic connected to this center. Inclusion criteria were age ≥ 20 years, ESRD treatment with HD for ≥ 3 months, Beck Depression Inventory (BDI-II) score ≥15, and major depressive disorder diagnosed by a single psychiatrist according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition, text revision (DSM-IV-TR) [20]. Exclusion criteria were HD due to acute renal failure, current hospitalization, current ongoing chemotherapy or radiotherapy, kidney transplantation planned within a few months, cognitive dysfunction or mental retardation, current substance abuse, lack of fluency in Korean, and current use of psychotropic medication.

This study was approved by the Institutional Review Board of the SMG-SNU Boramae Medical Center (IRB No. 16-2013-71). Informed consent was obtained from all participants after providing full information about the study. This study was registered on ClinicalTrials.gov (NCT02011139).

Organization of the CBT program (Table 1)

Summary of group cognitive behavioral therapy (CBT) themes

We modified the conventional CBT program because patients with ESRD have unique psychological characteristics. We organized the CBT program into three parts: In the initial phase (sessions 1–3), the program included an introduction, motivation, and muscle relaxation. In this phase, to raise participants’ motivation, we helped them set goals and provided information on the influence of stress on the body. Muscle relaxation included preparation for mindfulness meditation in the next phase. In the middle phase (sessions 4–7), skills for controlling negative feelings and pain were included with a body scan and mindfulness meditation [16,21]. In this phase, we encouraged participants to identify automatic thinking related to their emotions. The mindfulness meditation was divided into two parts: breathing and movement [16]. Through the meditation and self-soothing techniques, we helped participants overcome obsession with physical pain or automatic thinking and encouraged positive feelings. In the final phase, social skills training was included with anger management. For effective communication with their caregivers or medical staff, we included conversation skills training and practice in common situations with other participants [15,22]. To increase participants’ motivation and program effectiveness, we included a brief homework assignment between every session. We administrated the program once a week with the same psychologist.

Assessment measures

Except for self-rating questionnaires, all assessments were performed by a single psychiatrist who did not attend group CBT. Assessments were made on the same day as CBT, before the first and eighth sessions, and after the 12th session. Participants underwent HD after each group CBT. We evaluated QOL using the World Health Organization QOL assessment, WHOQOL-BREF [23]. WHOQOL-BREF total score was the sum of physical, psychological, social, and environmental domains, and two general items. Higher scores indicate better QOL. Depressive symptom severity was measured using BDI-II [24], a self-rating assessment, and by the Hamilton Rating Scale for Depression (HAM-D) [25], rated by a clinician. The BDI-II assessment has 21 items with a maximum score of 63, and the HAM-D assessment has 17 items with a maximum score of 52; higher scores indicate more severe depression. To evaluate anxiety and stress, participants completed the Beck Anxiety Inventory (BAI) [26] and 10 items of the Perceived Stress Scale (PSS) [27]. BAI is a self-reported questionnaire of 21 items on a four-point Likert scale, where a higher score indicates more severe anxiety. PSS is also a self-reported survey on a four-point Likert scale, where a higher score indicates a more stressful state. The Temperament and Character Inventory (TCI) [28] was included at baseline to evaluate the patients’ characteristics before group CBT. TCI is a self-rated assessment consisting of 240 yes-no questions. It has seven dimensions, including four traits (novelty seeking, NS; harm-avoidance, HA; reward-dependence, RD; and persistence, PE) and three characteristics (self-directedness, SDT; cooperativeness, CO; and self-transcendence, ST). Higher scores indicate that the participant has a greater degree of the specific characteristic, with a score of ≥ 55 classified as High, ≤ 45 as Low, and others as Medium, according to the TCI manual [28].

We evaluated the biochemical variables, Kt/V, albumin, serum creatinine (sCr), calcium/phosphorus (Ca/P), and interdialytic weight gain (IDWG), before and after 12 weeks of group CBT.

Statistical analysis

Generalized estimating equations (GEE) were used to compare BDI-II, HAM-D, BAI, PSS, and WHOQOL-BREF scores across the 12-week period. GEE have the benefit of analyzing correlations of repeated results within-subject. We used the Wilcoxon signed-rank test to compare biochemical marker levels before and after group CBT. All statistical analyses were performed using IBM SPSS Statistics ver. 20.0 (IBM Co., Armonk, NY, USA).

Results

The demographic characteristics of the participants are summarized in Table 2. Mean age was 56.4 ± 7.9 years (range, 48–67 years), mean education level was 10.4 ± 2.5 years (range, 6–13 years), and only one participant had a current occupation. Four participants had diabetes mellitus as the main underlying disease related to HD; other underlying diseases were hypertension or other/unknown cause. Although most of the participants had combined medical diseases including chronic lung disease, peptic ulcer, cerebrovascular disease, and coronary artery disease, their overall physical states were stable during CBT. Mean dialysis vintage was 2.5 ± 0.6 years (range, 1.7–3.5 years). One participant had a history of kidney transplantation.

Demographic data and biochemical variables during the group cognitive behavioral therapy (CBT)

At baseline, mean Kt/V was 1.3 ± 0.2 (range, 1.0–1.6); serum albumin was 4.0 ± 0.3 g/dL (range, 3.7–4.7 g/dL); sCr was 11.5 ± 3.5 mg/dL (range, 7.4–17.2 mg/dL); Ca/P was 8.4/5.1 ± 0.5/2.2 mg/dL (range, 7.5/2.7–8.8/8.7 mg/dL); IDWG was 2.6 ± 0.6 kg (range, 1.5–3.0 kg) (Table 2).

Before group CBT, participants had moderate to severe depressive moods as measured by self-rating (BDI-II; mean score, 32.0 ± 8.1; range, 22–43) and clinician rating (HAM-D; mean score, 19.4 ± 4.4; range, 14–26) (Fig. 1). The mean total QOL score measured by WHOQOL-BREF was 61.9 ± 11.3 (range, 48–82). Anxiety levels were mild (BAI; mean, 14.0 ± 10.4; range, 0–27), and stress levels were moderate (PSS; mean, 19.4 ± 7.1; range, 9–28). In the TCI, participants showed high HA (mean, 57.4 ± 11.4; range, 41–69), low RD (mean, 42.0 ± 10.1; range, 28–54), low SDT (mean, 41.4 ± 11.4; range, 25–56), and low CO (mean, 42.9 ± 4.4; range, 38–52) (Fig. 2).

Figure 1

Comparison of psychological measures during the cognitive behavioral therapy program. Generalized Estimating Equations were used

BAI, Beck Anxiety Inventory; BDI-II, Beck Depression Inventory II; HAM-D, Hamilton Rating Scale for Depression; PSS, Perceived Stress Scale; WHOQOL-BREF, World Health Organization Quality of Life scale, abbreviated version.

Figure 2

Personality dimensions of the participants (mean T scores of participants at baseline)

CO, cooperativeness; HA, harm-avoidance; NS, novelty seeking; PE, persistence; RD, reward-dependence; SDT, self-directedness; ST, self-transcendence; TCI, Temperament and Character Inventory.

After participants completed all 12 CBT sessions, mean Kt/V was 1.5 ± 0.3 (range, 1.2–2.0); serum albumin was 4.0 ± 0.2 g/dL (range, 3.8–4.3 g/dL); sCr was 10.3 ± 2.7 mg/dL (range, 7.2–13.5 mg/dL); Ca/P was 8.8/4.9 ± 0.6/1.0 mg/dL (range, 7.9/3.5–9.7/6.5 mg/dL); and IDWG was 2.4 ± 0.7 kg (range, 1.5–3.0 kg). In a Wilcoxon signed-rank test, Kt/V and sCr showed significant improvement (P = 0.063 and 0.043, respectively). Other variables did not show a significant change (Table 2).

Participants showed significant improvement in all rating scores compared to baseline (Fig. 1). QOL by WHOQOL-BREF showed significant improvement (mean, 84.1 ± 8.7; range, 71–92; P < 0.001). In mood scales, both BDI-II and HAM-D scores significantly decreased to normal or minimal depressive levels (BDI-II: mean, 6.1 ± 3.8; range, 2–12; P < 0.001 and HAM-D: mean, 5.7 ± 1.5; range, 4–8; P < 0.001). BAI and PSS scores also showed significant improvement after 12 weeks of group CBT (BAI: mean, 4.3 ± 3.4; range, 0–8; P < 0.001 and PSS: mean, 12.3 ± 3.0; range, 7–16; P < 0.001). WHOQOL-BREF scores and the self-rating BDI-II and BAI scales showed significant improvement continuously across the 12 weeks. HAM-D scores showed significant improvement by week 8; PSS showed significant improvement after week 8 (Fig. 1).

Discussion

After our 12-week group CBT program, ESRD patients undergoing HD showed significant improvements in WHOQOL-BREF, BDI-II, HAM-D, BAI, and PSS scores, and in sCr levels. WHOQOL-BREF, BDI-II, and BAI scores showed continuous improvement at each evaluation over the 12-week period. HAM-D scores improved at week 8 but not during last four weeks; PSS scores showed significant improvement after week 8.

We suspect that these results are related to the themes of the CBT program. Until the second evaluation period (starting at week 8), patients experienced mainly mindfulness meditation, correction of automatic thinking, and self-soothing techniques. Scores on objective mood (HAM-D) showed significant improvement in depressive symptoms starting at week 8, after the second period containing conventional CBT and mindfulness meditation. We expect that, with the accumulated effect of prior sessions, the terminal themes of the program such as anger management and communication skills help participants gain feelings of self-control, and these feelings might improve perceived stress. For QOL and subjective improvement of depression and anxiety, we think that most themes of our group CBT program might be helpful.

Mean baseline scores of BDI-II and HAM-D were 32 ± 8.10 and 19.43 ± 4.43, respectively. These scores are much higher than the suggested cut-off values for depression for ESRD patients undergoing HD in other studies (14–16 for BDI [22], and 10 for HAM-D [29]). The mean total score on the WHOQOL-BREF in our participants was 61.9 ± 11.3 at baseline. This score was similar to or higher than scores reported in other studies of elderly patients with chronic kidney disease or depression [30,31]. Compared with a QOL study of chronic kidney disease patients, our patients reported relatively low social domain and high environmental domain scores. We suppose that our patients’ relatively severe depressive symptoms and regular HD schedule might have caused a lower social domain score, while a stable national medical insurance and care system for ESRD in Korea might have caused a higher environmental score.

In TCI, participants showed high HA and low RD in trait dimensions and low SDT and low CO in character dimensions. High HA, low SDT, and low CO are related to depression [32]. Therefore, our participants had traits and characteristics consistent with depression. Throughout our program, they reported improvement of mood and QOL.

It is common for ESRD patients undergoing HD to experience low QOL, feelings of loss of control in their lives, depressive mood, and anxiety. These feelings often induce non-adherence to medical treatment [33]. In this study, improvement of the biochemical variables sCr and Kt/V suggests that our program induced better medical adherence. A previous study also reported improved IDWG following conventional CBT [12].

The main psychological mechanism in which mindfulness meditation reduces psychiatric problems including depression is reperceiving [34,35]. In mindfulness practice, moment-by-moment nonjudgmental awareness is essential. Through nonjudgmental awareness, one reperceives problems with objectivity and greater clarity [35]. This process helps one to control unpleasant sensations. This process is also related to self-regulation, decreased emotional reactivity, clarification of values, and cognitive-behavioral flexibility. Self-regulation provides coping skills and prevents maladaptive responses. Cognitive and behavioral flexibility induce adaptive responses. Values clarification facilitates choosing behaviors more congruent with one’s core values [34,35]. It has been reported that mindfulness is related to cortical midline structures (CMS), the amygdala, anterior insula, and lateral prefrontal cortex [35]. As the CMS is involved in emotional processing, this structure may have a role in self-referential thinking and emotional dysregulation in mood disorders [35,36]. Modifying the CMS has been suggested to be one of the key mechanisms of mindfulness [35].

We developed a group CBT program for ESRD patients undergoing HD who experience depression that addressed the patients’ psychological character. In our program, patients experienced psychoeducation, correction of automatic thinking, mindfulness meditation, and communication skills practice. As a result, participants showed significant improvements in QOL, depressive mood, anxiety, perceived stress, and biochemical marker levels. In a clinical situation, this group CBT program would be helpful for all depressive patients, especially those who cannot take psychiatric medications due to physical conditions or who show no significant improvement following medication. We expect that it would be easier to manage such a program if group members have a similar age and educational level.

Although our group CBT program was feasible and effective, some limitations exist. First, the sample size was small. Second, our participants had less comorbid illness and more medical stability than many other patients with ESRD. Additionally, we used small groups of 2 to 3 participants. These characteristics may have affected participant compliance and improvement. Third, this study was not controlled and did not use a blinded test. Fourth, we did not carry out a longitudinal follow-up after our group CBT program and therefore could not confirm the long-term effect. In the future, a randomized controlled study with a larger sample size and long-term observation will be needed.

In conclusion, our group CBT program, including mindfulness meditation and practical distress-relieving methods such as self-soothing, anger management, and communication skills practice in the framework of conventional CBT, was feasible and effective. Our program was applied to chronic ESRD patients undergoing HD and resulted in improvement in overall psychiatric problems such as low QOL, depressive mood, anxiety, and stress, which might influence patients’ medical compliance.

Acknowledgments

This work was supported by a clinical research grant-in-aid from the SMG-SNU Boramae Medical Center (16-2013-71).

Notes

Conflicts of interest

All authors had no conflicts of interest to declare.

References

1. Christensen AJ, Ehlers SL. Psychological factors in end-stage renal disease: an emerging context for behavioral medicine research. J Consult Clin Psychol 70:712–724. 2002;10.1037/0022-006X.70.3.712. 12090378.
2. Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 45:658–666. 2005;10.1053/j.ajkd.2004.12.021. 15806468.
3. Cukor D, Coplan J, Brown C, et al. Depression and anxiety in urban hemodialysis patients. Clin J Am Soc Nephrol 2:484–490. 2007;10.2215/CJN.00040107. 17699455.
4. Hedayati SS, Bosworth HB, Kuchibhatla M, Kimmel PL, Szczech LA. The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney Int 69:1662–1668. 2006;10.1038/sj.ki.5000308. 16598203.
5. Kimmel PL, Emont SL, Newmann JM, Danko H, Moss AH. ESRD patient quality of life: symptoms, spiritual beliefs, psychosocial factors, and ethnicity. Am J Kidney Dis 42:713–721. 2003;10.1016/S0272-6386(03)00907-7. 14520621.
6. Drayer RA, Piraino B, Reynolds CF 3rd, et al. Characteristics of depression in hemodialysis patients: symptoms, quality of life and mortality risk. Gen Hosp Psychiatry 28:306–312. 2006;10.1016/j.genhosppsych.2006.03.008. 16814629.
7. Cukor D, Rosenthal DS, Jindal RM, Brown CD, Kimmel PL. Depression is an important contributor to low medication adherence in hemodialyzed patients and transplant recipients. Kidney Int 75:1223–1229. 2009;10.1038/ki.2009.51. 19242502.
8. Hedayati SS, Bosworth HB, Briley LP, et al. Death or hospitalization of patients on chronic hemodialysis is associated with a physician-based diagnosis of depression. Kidney Int 74:930–936. 2008;10.1038/ki.2008.311. 18580856.
9. Kurella M, Kimmel PL, Young BS, Chertow GM. Suicide in the United States end-stage renal disease program. J Am Soc Nephrol 16:774–781. 2005;10.1681/ASN.2004070550. 15659561.
10. Kimmel PL, Weihs K, Peterson RA. Survival in hemodialysis patients: the role of depression. J Am Soc Nephrol 4:12–27. 1993;8400064.
11. Binik YM, Devins GM, Barre PE, et al. Live and learn: patient education delays the need to initiate renal replacement therapy in end-stage renal disease. J Nerv Ment Dis 181:371–376. 1993;10.1097/00005053-199306000-00006. 8501458.
12. Cukor D, Ver Halen N, Asher DR, et al. Psychosocial intervention improves depression, quality of life, and fluid adherence in hemodialysis. J Am Soc Nephrol 25:196–206. 2014;10.1681/ASN.2012111134. 3871769.
13. Friend R, Singletary Y, Mendell NR, Nurse H. Group participation and survival among patients with end-stage renal disease. Am J Public Health 76:670–672. 1986;10.2105/AJPH.76.6.670. 3706594. 1646784.
14. Hener T, Weisenberg M, Har-Even D. Supportive versus cognitive-behavioral intervention programs in achieving adjustment to home peritoneal kidney dialysis. J Consult Clin Psychol 64:731–741. 1996;10.1037/0022-006X.64.4.731. 8803363.
15. Leake R, Friend R, Wadhwa N. Improving adjustment to chronic illness through strategic self-presentation: an experimental study on a renal dialysis unit. Health Psychol 18:54–62. 1999;10.1037/0278-6133.18.1.54. 9925046.
16. Ma SH, Teasdale JD. Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. J Consult Clin Psychol 72:31–40. 2004;10.1037/0022-006X.72.1.31. 14756612.
17. Kabat-Zinn J. Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress, Pain, and Illness New York: Bantam Books; 1990.
18. Reilly-Spong M, Reibel D, Pearson T, Koppa P, Gross CR. Telephone-adapted mindfulness-based stress reduction (tMBSR) for patients awaiting kidney transplantation: Trial design, rationale and feasibility. Contemp Clin Trials 42:169–184. 2015;10.1016/j.cct.2015.03.013. 25847578. 4450136.
19. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy of Depression New York: Guilford Press; 1979.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th Editionth ed. Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
21. Williams M, Penman D. Mindfulness: A Practical Guide to Finding Peace in a Frantic World London: Piatkus Books; 2011.
22. Hedayati SS, Yalamanchili V, Finkelstein FO. A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. Kidney Int 81:247–255. 2012;10.1038/ki.2011.358. 3258342.
23. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 28:551–558. 1998;10.1017/S0033291798006667.
24. Beck AT, Steer RA, Brown GK. Maunal for the Beck Depression Inventory-II 2nd editionth ed. San Antonio: The Psychological Corporation; 1996.
25. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62. 1960;10.1136/jnnp.23.1.56. 14399272. 495331.
26. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56:893–897. 1988;10.1037/0022-006X.56.6.893. 3204199.
27. Cohen S, Williamson G. Perceived stress in a probability sample of the United States. In : Spacapan S, Oskamp S, eds. The Social Psychology of Health: Claremont Symposium on Applied Social Psychology Newbury Park: Sage. p. 31–67. 1988.
28. Cloninger RC, Przybeck TR, Svrakic DM, Wetzel RD. The Temperament and Character Inventory (TCI): A Guide to Its Development and Use. Center for Psychobiology of Personality St. Louis: Washington University; 1994.
29. Gençöz F, Gençöz T, Soykan A. Psychometric properties of the Hamilton Depression Rating Scale and other physician-rated psychiatric scales for the assessment of depression in ESRD patients undergoing hemodialysis in Turkey. Psychol Health Med 12:450–459. 2007;10.1080/13548500600892054. 17620209.
30. Chang YC, Ouyang WC, Lu MC, Wang JD, Hu SC. Levels of depressive symptoms may modify the relationship between the WHOQOL-BREF and its determining factors in community-dwelling older adults. Int Psychogeriatr 28:591–601. 2016;10.1017/S1041610215002276.
31. Tsai YC, Hung CC, Hwang SJ, et al. Quality of life predicts risks of end-stage renal disease and mortality in patients with chronic kidney disease. Nephrol Dial Transplant 25:1621–1626. 2010;10.1093/ndt/gfp671.
32. Hirano S, Sato T, Narita T, et al. Evaluating the state dependency of the Temperament and Character Inventory dimensions in patients with major depression: a methodological contribution. J Affect Disord 69:31–38. 2002;10.1016/S0165-0327(00)00329-3. 12103449.
33. Christensen AJ, Smith TW, Turner CW, Cundick KE. Patient adherence and adjustment in renal dialysis: a person x treatment interactive approach. J Behav Med 17:549–566. 1994;10.1007/BF01857597. 7739030.
34. Shapiro SL, Carlson LE, Astin JA, Freedman B. Mechanisms of mindfulness. J Clin Psychol 62:373–386. 2006;10.1002/jclp.20237.
35. Marchand WR. Mindfulness meditation practices as adjunctive treatments for psychiatric disorders. Psychiatr Clin North Am 36:141–152. 2013;10.1016/j.psc.2013.01.002. 23538083.
36. Northoff G, Bermpohl F. Cortical midline structures and the self. Trends Cogn Sci 8:102–107. 2004;10.1016/j.tics.2004.01.004.

Article information Continued

Figure 1

Comparison of psychological measures during the cognitive behavioral therapy program. Generalized Estimating Equations were used

BAI, Beck Anxiety Inventory; BDI-II, Beck Depression Inventory II; HAM-D, Hamilton Rating Scale for Depression; PSS, Perceived Stress Scale; WHOQOL-BREF, World Health Organization Quality of Life scale, abbreviated version.

Figure 2

Personality dimensions of the participants (mean T scores of participants at baseline)

CO, cooperativeness; HA, harm-avoidance; NS, novelty seeking; PE, persistence; RD, reward-dependence; SDT, self-directedness; ST, self-transcendence; TCI, Temperament and Character Inventory.

Table 1

Summary of group cognitive behavioral therapy (CBT) themes

Session Contents
1 Introduction of CBT program, therapist, and group members
2 Talking about stress regarding chronic kidney disease and hemodialysis
Understanding of stress and depression
Progressive muscular relaxation
3 Finding values
Setting goals
Progressive muscular relaxation
4 Recognizing automatic thinking and relationship between thinking and emotion
Body scan practice
5 Mindfulness meditation I (breathing)
6 Mindfulness meditation II (movement)
7 Self-soothing techniques: self-comfort for experiencing positive feelings
8 Anger management
9 Effective communication skills I (introduction)
10 Effective communication skills II (practicing): delivery of feeling, needs, favor
11 Effective communication skills III (practicing): listening, compromising, acceptance
12 Summary of the program themes
Making goals
Planning for stress management

Table 2

Demographic data and biochemical variables during the group cognitive behavioral therapy (CBT)

Participant Sex/age (yr) Education (yr) Occupation Main disease associate HD Previous KT Dialysis vintage (yr) Kt/V Albumin (g/dL) sCr* (mg/dL) Ca/P (mg/dL) IDWG (kg)





Before After Before After Before After Before After Before After
A F/65 9 No Others No 3.0 1.3 1.3 3.9 3.9 14.3 13.2 8.8/2.7 8.8/4.1 2.5 3.0
B F/67 9 No Unknown No 2.4 1.6 2.0 3.9 3.8 8.9 8.3 8.8/3.0 8.1/3.5 1.5 1.5
C M/55 6 No DM No 2.1 1.3 1.7 3.7 4.1 9.7 8.5 7.5/8.7 8.8/6.0 3.0 3.0
D M/61 12 No DM Yes 2.0 1.1 1.5 3.7 3.8 9.9 8.5 8.5/3.6 7.9/4.6 3.0 3.0
E M/49 12 Yes HTN No 1.7 1.2 1.2 4.7 4.3 13.2 13.5 8.8/4.7 9.3/4.7 4.0 2.8
F F/50 13 No DM No 3.5 1.5 1.5 4.1 4.2 7.4 7.2 8.1/6.0 9.7/6.5 4.0 1.8
G M/48 12 No DM No 2.5 1.0 1.4 4.1 3.9 17.2 12.9 8.2/6.9 9.2/4.6 2.5 2.0

Ca/P, calcium/phosphorus; DM, diabetes mellitus; F, Female; HD, hemodialysis; HTN, hypertension; IDWG, interdialytic weight gain; KT, kidney transplantation; M, male; sCr, serum creatinine. Before, before group CBT; After, after group CBT.

*

P = 0.043 by Wilcoxon signed ranks test.